It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Quantifying tumor burden is important for following the natural history of orthotopic colon cancer and therapeutic efficacy. Bioluminescence imaging (BLI) is commonly used for such assessment and has both advantages and limitations. We compared BLI and magnetic resonance imaging (MRI) for quantifying orthotopic tumors in a mouse model of colon cancer. Among sequences tested, T2-based MRI imaging ranked best overall for colon cancer border delineation, contrast, and conspicuity. Longitudinal MRI detected tumor outside the colon, indistinguished by BLI. Colon tumor weights calculated from MRI in vivo correlated highly with tumor weights measured ex vivo whereas the BLI signal intensities correlated relatively poorly and this difference in correlations was highly significant. This suggests that MRI may more accurately assess tumor burden in longitudinal monitoring of orthotopic colon cancer in this model as well as in other models.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The University of Texas MD Anderson Cancer Center, Department of Cancer Systems Imaging, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
2 Tel-Aviv University, Department of Oncology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-HaShomer, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
3 The University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
4 U.T.-M.D. Anderson Cancer Center, Department of Biostatistics, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
5 Division of Cancer Medicine, U.T.-M.D. Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)
6 MUSC College of Medicine, Dean’s Office, Charleston, USA (GRID:grid.259828.c) (ISNI:0000 0001 2189 3475)
7 The University of Texas MD Anderson Cancer Center, Department of Cancer Systems Imaging, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); U.T.-M.D. Anderson Cancer Center, Department of Radiology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776)